Breast Cancer Let's look under the Hood

May 7,, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Breast Cancer Let's look under the Hood


Breast Cancer patients the structure and biological behavior of a cell is determined by the pattern of gene expression within that
cell. Each human cell contains approximately three billion
base pairs, which encode between 50 000 to 100 000
genes [1±3]. In any given cell only a small fraction of
these genes is being actively transcribed. Breast Cancer can be
regarded as a genetic disease occurring as a result of
progressive accumulation of genetic aberrations [4].
Neoplastic cells have numerous acquired genetic abnormalities
including aneuploidy, chromosomal rearrangements,
amplifications, deletions, gene rearrangements,
and loss or gain of function mutations.

Breast cancer is a disease in which certain cells in the breast
become abnormal and multiply without control or order to form a
tumor. The most common form of breast cancer begins in cells
lining the ducts that carry milk to the nipple (ductal cancer).
Other forms of breast cancer begin in the glands that produce
milk (lobular cancer) or in other parts of the breast

Tumors that begin at one site and then spread to other areas
of the body are called metastatic breast cancers.
Hereditary breast cancers tend to occur earlier in life than
noninherited (sporadic) cases and are more likely to involve both breast

Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid Medical breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.